Phase II For Interferon Enhancing Therapy
Posted: Fri Jan 28, 2005 9:12 am
This isn't all that exciting, but it's something...
Transition Therapeutics Commences Enrolment for Multiple Sclerosis Phase II Clinical Trial
Jan. 28 - Transition Therapeutics Inc., announced today that patient enrolment has commenced for a Phase II clinical trial of its Interferon Enhancing Therapy ("MS-I.E.T.") in patients with multiple sclerosis ("MS"). MS-I.E.T. combines interferon-(B) with Transition's enhancing agent, EMZ701, with the goal of improving outcomes in MS patients without adding toxicity.
"With a real medical need for effective MS therapies, this trial is designed to demonstrate the ability of EMZ701 to increase interferon efficacy and recover a large patient population that has lost or is losing responsiveness to current interferon therapies." said Dr. Tony Cruz, Chairman and CEO of Transition.
The Phase II study will enroll 40 relapsing / remitting MS patients
currently on interferon-(B) therapy showing renewed disease activity as
evidenced by MRI changes. After monitoring MRI activity for 12 weeks while on interferon-(B) therapy alone, patients will receive weekly EMZ701 treatments in addition to their standard interferon-(B) therapy for 24 weeks.
In a Phase I clinical trial, Transition's EMZ701 was well tolerated with
a good safety profile. In addition, pre-clinical studies have demonstrated
that MS-I.E.T. is significantly more effective than interferon-(B) alone in
reducing both symptoms and pathologies associated with MS in multiple animal models. Transition's interferon enhancing technologies have also demonstrated more potent anti-viral and anti-proliferative effects than interferon alone and may potentially have applications in hepatitis C, hepatitis B and cancer.
Transition is focused on the clinical development of its interferon enhancing therapies for MS, hepatitis C and cancer. Worldwide sales of interferon products are estimated to be in excess of US$ 5 billion annually.
http://www.newswire.ca/en/releases/arch ... c7991.html
Transition Therapeutics Commences Enrolment for Multiple Sclerosis Phase II Clinical Trial
Jan. 28 - Transition Therapeutics Inc., announced today that patient enrolment has commenced for a Phase II clinical trial of its Interferon Enhancing Therapy ("MS-I.E.T.") in patients with multiple sclerosis ("MS"). MS-I.E.T. combines interferon-(B) with Transition's enhancing agent, EMZ701, with the goal of improving outcomes in MS patients without adding toxicity.
"With a real medical need for effective MS therapies, this trial is designed to demonstrate the ability of EMZ701 to increase interferon efficacy and recover a large patient population that has lost or is losing responsiveness to current interferon therapies." said Dr. Tony Cruz, Chairman and CEO of Transition.
The Phase II study will enroll 40 relapsing / remitting MS patients
currently on interferon-(B) therapy showing renewed disease activity as
evidenced by MRI changes. After monitoring MRI activity for 12 weeks while on interferon-(B) therapy alone, patients will receive weekly EMZ701 treatments in addition to their standard interferon-(B) therapy for 24 weeks.
In a Phase I clinical trial, Transition's EMZ701 was well tolerated with
a good safety profile. In addition, pre-clinical studies have demonstrated
that MS-I.E.T. is significantly more effective than interferon-(B) alone in
reducing both symptoms and pathologies associated with MS in multiple animal models. Transition's interferon enhancing technologies have also demonstrated more potent anti-viral and anti-proliferative effects than interferon alone and may potentially have applications in hepatitis C, hepatitis B and cancer.
Transition is focused on the clinical development of its interferon enhancing therapies for MS, hepatitis C and cancer. Worldwide sales of interferon products are estimated to be in excess of US$ 5 billion annually.
http://www.newswire.ca/en/releases/arch ... c7991.html